Recently, Hengrui Pharmaceutical subsidiary Shanghai Shengdi Pharmaceutical Co., Ltd. received the "Pharmaceutical Registration Certificate" issued by the State Drug Administration (NMPA) to approve the company's independent PD-L1 inhibitor Adeberley Midgrot (iResearch Profit) combined with first-line therapy for patients with Platinum and Ryposidin for patients with ES-SCLC (ES-SCLC). Adebergazab became my country's first independent R & D PD-L1 inhibitor to be approved by small cell lung cancer indications, bringing new treatment options to patients. At this point, Hengrui Pharmaceutical has been approved to be listed 12 innovative medicines.